31 January 2012
Fierce competition now demands the swift conversion of new medical concepts into marketable products and this requires the technologist to recruit the help of inventive designers to realise the full potential of the product.
Steritrox Ltd, the leaders in rapid room sanitizing and disinfection, developed the Meditrox 100 in response to one of the major challenges facing hospital administrators, namely the eradication of cross infection within the clinical environment. Patients and staff benefit from the innovative UK technology employed in the Meditrox system, which removes airborne and surface borne infection quickly and safely, leaving a whole hospital room decontaminated within less than one hour.
The patented system converts oxygen and water through the science of advanced oxidation into a highly effective biocidal vapour. Unlike other solutions that rely on chemical agents such as hydrogen peroxide and chlorine to perform the decontamination function, Meditrox has developed a process that uses a combination of water vapour and ionised oxygen as the primary ingredients.
Meditrox was deployed at the Royal Preston Hospital as part of a 3 month trial for the Trust to evaluate the benefits over existing Hydrogen Peroxide based 'fogging' systems. The hospital has around 750 beds of which 14% are single patient rooms. Meditrox replaced the HPV systems for the routine cleaning of rooms following the discharge of patients with C.Difficile and was also used to implement a routine of scheduled sluice room cleaning which had not previously been possible due to time limitations of HPV. This system presented significant time saving over the existing HPV technology when decontaminating side rooms, reducing the wait for the beds to become available to less than 3 hours compared to 5 or more previously, commented Debbie Fielding the Associate Director of Infection Prevention and Control at Lancashire Teaching Hospitals NHS Foundation Trust.
Renfrew Group International provided Steritrox with innovative solutions to the component packaging and the user interfaces, which were designed for ease of use and minimal maintenance. Concepts like these evolve from tandem thinking, a union of the creative and the technical in a way proven to deliver robust intellectual property. The consultancy's approach to product design and engineering also ensures the rapid conversion of a laboratory based technology to a market ready product, though strategic prototyping and the provision of low volume production samples for testing and clinical trials.
For more information, contact:
Mike Phillips
Renfrew Group International
Tel: 0116 253 1961
Website: www.renfrewgroup.com
